Form D · Biotechnology

OBALON THERAPEUTICS INC

Carlsbad, CA · CIK 0001427570

Offering snapshot reported Aug 29, 2018 · SEC filing

Reported sold
$10M
Offering amount: $10M
Investors reported
21
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 23, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 29, 2018Initial$10,000,000No comparison21SEC filing
Oct 2, 2014Initial$15,899,998No comparison5SEC filing
Dec 19, 2012Initial$5,000,000No comparison1SEC filing
May 17, 2012Initial$16,523,014No comparison3SEC filing
Mar 26, 2012Initial$1,500,000No comparison2SEC filing
Feb 13, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-320244

Source: Form D, filed Aug 29, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mark Brister Executive
Raymond Dittamore Director
Doug Fisher Director
Douglas Fisher Director
Les Howe Director
Kelly Huang, Ph.D. Executive
Kim Puloma Kamdar Director
Kim Kamdar, Ph.D. Director
David Moatazedi Director
William J. Plovanic Executive
Andrew Rasdal Director, Executive
Douglas C. Sampson Director
Sharon Stevenson Director
Sharon Stevenson, Dvm Ph.D. Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5421 Avenida Encinas, Suite F
Carlsbad, CA, 92008